In Vitro and Clinical Evaluations of UGT1A1‐, P‐gp‐, OATP1B1‐, and BCRP‐Mediated Drug–Drug Interactions of Belumosudil, a Potent ROCK2 Inhibitor

Documenti analoghi

• Pharmacokinetics of Belumosudil and Its Metabolites in Individuals With Hepatic Impairment
  di: Olivier Schueller, et al.
  Pubblicazione: (2025)
• Two‐Part Phase 1 Study to Evaluate the Taste Profile of Novel Belumosudil Oral Suspensions and Assess the Relative Bioavailability and Food Effect of the Selected Belumosudil Oral Suspension Compared With Oral Tablet Reference in Healthy Male Participants
  di: Olivier Schueller, et al.
  Pubblicazione: (2024)
• Comprehensive Evaluation of OATP‐ and BCRP‐Mediated Drug–Drug Interactions of Methotrexate Using Physiologically‐Based Pharmacokinetic Modeling
  di: Sejung Hwang, et al.
  Pubblicazione: (2024)
• A Clinical Practice Perspective on the Evaluation of OATP1B1‐associated Drug Interactions
  di: Céline K. Stäuble, et al.
  Pubblicazione: (2024)
• Biomarker‐Based Prediction of OATP1B1 Activity in Clinical Routine—Investigating Coproporphyrins as Markers for Drug–Drug–Gene Interactions
  di: Leila Potzel, et al.
  Pubblicazione: (2026)